ArticleGene therapy2013
Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation.
Article in Gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Resistance to oncolytic virotherapy: Multidimensional mechanisms and therapeutic breakthroughs (Review).International journal of molecular medicine · 2025Review
- Review
- Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses.Frontiers in immunology · 2024Review
- Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?Journal for immunotherapy of cancer · 2023Review
- In Vivo Oncolytic Virotherapy in Murine Models of Hepatocellular Carcinoma: A Systematic Review.Vaccines · 2022Review
- Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.Frontiers in cellular neuroscience · 2022Review
- The role of collagen in cancer: from bench to bedside.Journal of translational medicine · 2019Review
- GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo.Acta pharmacologica Sinica · 2018Article
- Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.Gene therapy · 2018Article
- Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.Acta biomaterialia · 2017Article
- Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.Frontiers in immunology · 2017Review
- Recent advances in oncolytic adenovirus therapies for cancer.Current opinion in virology · 2016Review
- GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells.Oncotarget · 2016Article
- A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.Oncotarget · 2015Article
- Tamoxifen improves cytopathic effect of oncolytic adenovirus in primary glioblastoma cells mediated through autophagy.Oncotarget · 2015Article
- Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Targeting tumor vasculature through oncolytic virotherapy: recent advances.Oncolytic virotherapy · 2015Review
- Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.Therapeutic delivery · 2015Review
- Oncolytic adenoviruses: A thorny path to glioma cure.Genes & diseases · 2014Article
- Tumor Restrictions to Oncolytic Virus.Biomedicines · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Conditionally replicating adenoviruses (CRAd) are a promising class of gene therapy agents that can overcome already known glioblastoma (GBM) resistance mechanisms but have limited distribution upon direct intratumoral (i.t.) injection. Collagen bundles in the extracellular matrix (ECM) have an important role in inhibiting virus distribution. In fact, ECM pre-treatment with collagenases improves virus distributions to tumor cells. Matrix metalloproteinases (MMPs) are an endogenous class of collagenases secreted by tumor cells whose function can be altered by different drugs including anti-angiogenic agents, such as bevacizumab. In this study we hypothesized that upregulation of MMP activity during anti-angiogenic therapy can improve CRAd-S-pk7 distribution in GBM. We find that MMP-2 activity in human U251 GBM xenografts increases (*P=0.03) and collagen IV content decreases (*P=0.01) during vascular endothelial growth factor (VEGF-A) antibody neutralization. After proving that collagen IV inhibits CRAd-S-pk7 distribution in U251 xenografts (Spearman rho=-0.38; **P=0.003), we show that VEGF-blocking antibody treatment followed by CRAd-S-pk7 i.t. injection reduces U251 tumor growth more than each individual agent alone (***P<0.0001). Our data propose a novel approach to improve virus distribution in tumors by relying on the early effects of anti-angiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.